UK markets closed

Sangamo Therapeutics, Inc. (SGMO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.5115+0.0264 (+5.44%)
At close: 04:00PM EDT
0.5194 +0.01 (+1.54%)
After hours: 07:22PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 104.18M
Enterprise value 61.28M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.51
Price/book (mrq)1.26
Enterprise value/revenue 0.35
Enterprise value/EBITDA -0.63

Trading information

Stock price history

Beta (5Y monthly) 1.35
52-week change 3-69.09%
S&P500 52-week change 320.07%
52-week high 31.7800
52-week low 30.2900
50-day moving average 30.7986
200-day moving average 30.7319

Share statistics

Avg vol (3-month) 32.39M
Avg vol (10-day) 31.54M
Shares outstanding 5203.67M
Implied shares outstanding 6203.67M
Float 8165.08M
% held by insiders 19.45%
% held by institutions 147.59%
Shares short (28 Mar 2024) 411.41M
Short ratio (28 Mar 2024) 45.05
Short % of float (28 Mar 2024) 46.39%
Short % of shares outstanding (28 Mar 2024) 45.60%
Shares short (prior month 29 Feb 2024) 410.06M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -146.30%
Operating margin (ttm)-2,476.15%

Management effectiveness

Return on assets (ttm)-17.60%
Return on equity (ttm)-136.47%

Income statement

Revenue (ttm)176.23M
Revenue per share (ttm)1.01
Quarterly revenue growth (yoy)-92.50%
Gross profit (ttm)N/A
EBITDA -87.43M
Net income avi to common (ttm)-257.83M
Diluted EPS (ttm)-1.4800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)81M
Total cash per share (mrq)0.45
Total debt (mrq)38.1M
Total debt/equity (mrq)45.97%
Current ratio (mrq)1.98
Book value per share (mrq)0.47

Cash flow statement

Operating cash flow (ttm)-224.84M
Levered free cash flow (ttm)-90.74M